Ultragenyx Pharmaceutical reported $136 million in total revenue for Q1 2026, with key products Crysvita and Dojolvi contributing $93 million and $18 million respectively. The company reaffirmed its 2026 revenue guidance of $730 million to $760 million and expects combined R&D and SG&A expenses to remain flat or slightly decrease compared to 2025. Ultragenyx highlighted promising long-term Phase 1/2 data for GTX-102 in treating Angelman syndrome, with Phase 3 results expected in the second half of 2026. The company is also progressing with regulatory reviews for gene therapies DTX401 and UX111, targeting approvals later this year, and aims for profitability in 2027.
Since 2022, the amount of credit card debt that is 90 days overdue has almost doubled, indicating growing financial stress among borrowers. However, the rate of new delinquencies has not increased, suggesting that while existing overdue balances are ...
Zoom Communications has been upgraded to a buy rating following recent underperformance that has eased valuation concerns. Despite modest 4.9% year-over-year revenue growth, Zoom shows operational strength with a strong cash position and a 24.6% GAAP...
Schall, Brown & Schwartz LLP announced a class action lawsuit against Replimune Group for allegedly making false and misleading statements about its Biologics License Application (BLA) to the FDA. The company reportedly submitted incomplete and unpla...
Replimune Group faces a class action lawsuit alleging violations of securities laws due to false and misleading statements about its FDA study design in its Biologics License Application. The lawsuit covers shareholders who bought Replimune shares be...
Nvidia's shares rose nearly 6% in premarket trading after the company reported earnings that exceeded expectations and provided strong revenue guidance. CEO Jensen Huang highlighted that AI demand has reached an inflection point, with a significant i...
